Celgene Backs into Biotech
Executive Summary
A marketed product, a second in registration, and $300 million cash enabled Celgene to acquire a biotech capability and expand beyond its roots as a chiral chemistry company. But it took 15 years to get there. Formed as a bioremediation and chiral chemistry company in 1986, it struggled with those businesses. However, its chemical mentality led to in-licensing rights to thalidomide, which subsequently demonstrated activity in cancer. It reached profitability last year on sales of that drug, and with a chiral form of Ritalin pending approval, it finally had the resources to backfill a biology capability. Its purchase of Signal Pharmaceuticals gives it that and is its solution to the late-stage model problem of how to move beyond initial products and leverage a commercial infrastructure.
You may also be interested in...
Millennium: The Risks of Forward Integration
Millennium Pharmaceuticals has been spending much of the new century building a development organization. Much of this nuts-and-bolts endeavor came out of its acquisition of Cor Therapeutics in 2001, a transforming transaction that has delivered only mixed results, and has now put the company on a hard-to-steer and equally hard-to-alter course.
CMS-Manufacturer Discussion Of Medicare Price Negotiation Program Scheduled For 13 December
Agency reaches out to manufacturers as it develops its approach to implementing the controversial new program.
Minute Insight: Activ Surgical Wins CE Mark For ActivSight
After winning US FDA clearance in 2021, Activ Surgical now also received the green light to market its visualization module for surgeons in Europe.